ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

US · FDA approval, new medicine

Treosulfan (Grafapex)

For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome

Approved 21 Jan 2025

Research

Haematology · Haematologica · 2026-01-29

Subgroup analysis of a phase 3 trial in 352 AML patients undergoing alloHCT: treosulfan-fludarabine vs reduced-intensity busulfan-fludarabine improved 24-month event-free survival (65% vs 53%) and lowered extensive chronic GvHD (15.1% vs 28.1%).

Secondary analysisn = 352
Stölzel et al. GvHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.